Anti-Androgen - Androgen Synthesis Inhibitors

Anti-Androgen - Androgen Synthesis Inhibitors is a therapeutic class of antineoplastic hormonal agents that suppress the body’s production of androgens rather than directly blocking the androgen receptor These medications, exemplified by abiraterone acetate, work primarily by selectively inhibiting the cytochrome P450 17A1 (CYP17) enzyme complex, thereby halting steroid biosignaling in the testes, adrenal glands, and tumor tissue itself

Anti-Androgen - Androgen Synthesis Inhibitors is a therapeutic class of antineoplastic hormonal agents that suppress the body’s production of androgens rather than directly blocking the androgen receptor By depleting serum and intratumoral levels of testosterone and dihydrotestosterone, this class is primarily utilized in the management of advanced prostate cancer, particularly metastatic castration-resistant and castration-sensitive prostate cancer

These medications, exemplified by abiraterone acetate, work primarily by selectively inhibiting the cytochrome P450 17A1 (CYP17) enzyme complex, thereby halting steroid biosignaling in the testes, adrenal glands, and tumor tissue itself By depleting serum and intratumoral levels of testosterone and dihydrotestosterone, this class is primarily utilized in the management of advanced prostate cancer, particularly metastatic castration-resistant and castration-sensitive prostate cancer

These medications, exemplified by abiraterone acetate, work primarily by selectively inhibiting the cytochrome P450 17A1 (CYP17) enzyme complex, thereby halting steroid biosignaling in the testes, adrenal glands, and tumor tissue itself By depleting serum and intratumoral levels of testosterone and dihydrotestosterone, this class is primarily utilized in the management of advanced prostate cancer, particularly metastatic castration-resistant and castration-sensitive prostate cancer